Olanzapine-induced insulin resistance may occur via attenuation of central K ATP channel-activation.
Level 5 - mechanism / opinion, no new human data
Preclinical animal mechanism study evaluating central pathways via intracerebroventricular injection.
PubMed 33434724 · doi:10.1016/j.schres.2020.12.005
What was done
Researchers investigated whether the atypical antipsychotic olanzapine causes insulin resistance by disrupting central nervous system ATP-sensitive potassium (K_ATP) channel signaling. The K_ATP channel activator diazoxide was administered via intracerebroventricular (ICV) injection alone and in combination with olanzapine to assess effects on hepatic glucose production and peripheral glucose utilization.
What was found
The abstract reports no numerical values, effect sizes, or statistical metrics. ICV diazoxide suppressed hepatic glucose production and stimulated peripheral glucose utilization. Olanzapine inhibited the effects of central K_ATP channel activation on peripheral glucose utilization, disrupting whole-body insulin sensitivity, while leaving central K_ATP channel-mediated suppression of hepatic glucose production intact.
Why it matters
This study points to a specific central nervous system pathway through which olanzapine may acutely impair glucose utilization, offering a potential mechanistic explanation for antipsychotic-induced insulin resistance that occurs independently of weight gain.
Limits
The study is preclinical animal research using central drug infusions; no species, sample size, doses, or quantitative data are provided in the abstract. Clinical applicability to humans taking oral antipsychotics remains to be established.
Cited by
- partial Atypical antipsychotics with the suffix '-apine' promote weight gain, likely mediated by hypothalamic insulin resistance that reduces satiety signaling.